Changes to the Code
H.R. 3443 · When Minutes Count for Emergency Medical Patients Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1315a Center for Medicare and Medicaid Innovation
3 changes the bill asks for here, 3 carried out
- Carried out:
in subparagraph (A), in the third sentence, by inserting
, and shall include the model described in subparagraph (B)(xxviii)
before the period at the end; and - Carried out:
in subparagraph (B), by adding at the end the following new clause:
(xxviii) The When Minutes Count for EMS Patients Model described in subsection (h).; and
- Carried out:
by adding at the end the following new subsection:
(h) When Minutes Count for EMS Patients Model.— (1) In general.— For purposes of subsection (b)(2)(B)(xxviii), the When Minutes Count for EMS Patients Model described in this subsection is a model that provides supplemental payment for ground and air ambulance services under …
§ 1315a(b)Testing of models (phase I)(1)–(2)
Start of § 1315a to (b) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1) | (1) In general | (1) In general | ||
| The CMI shall test payment and service delivery models in accordance with selection criteria under paragraph (2) to determine the effect of applying such models under the applicable subchapter (as defined in subsection (a)(4)(B)) on program expenditures under such subchapters and the quality of care received by individuals receiving benefits under such subchapter. | The CMI shall test payment and service delivery models in accordance with selection criteria under paragraph (2) to determine the effect of applying such models under the applicable subchapter (as defined in subsection (a)(4)(B)) on program expenditures under such subchapters and the quality of care received by individuals receiving benefits under such subchapter. | |||
| (2) | (2) Selection of models to be tested | (2) Selection of models to be tested | ||
| (2)(A) | (A) In general | (A) In general | ||
| The Secretary shall select models to be tested from models where the Secretary determines that there is evidence that the model addresses a defined population for which there are deficits in care leading to poor clinical outcomes or potentially avoidable expenditures. The Secretary shall focus on models expected to reduce program costs under the applicable subchapter while preserving or enhancing the quality of care received by individuals receiving benefits under such subchapter. The models selected under this subparagraph may include, but are not limited to, the models described in subparagraph (B). | The Secretary shall select models to be tested from models where the Secretary determines that there is evidence that the model addresses a defined population for which there are deficits in care leading to poor clinical outcomes or potentially avoidable expenditures. The Secretary shall focus on models expected to reduce program costs under the applicable subchapter while preserving or enhancing the quality of care received by individuals receiving benefits under such subchapter. The models selected under this subparagraph may include, but are not limited to, the models described in subparagraph (B)[inserted: , and shall include the model described in subparagraph (B)(xxviii)]. | |||
| (2)(B) | (B) Opportunities | (B) Opportunities | ||
| The models described in this subparagraph are the following models: | The models described in this subparagraph are the following models: | |||
| (2)(B)(i) | (i) | (i) | ||
| Promoting broad payment and practice reform in primary care, including patient-centered medical home models for high-need applicable individuals, medical homes that address women’s unique health care needs, and models that transition primary care practices away from fee-for-service based reimbursement and toward comprehensive payment or salary-based payment. | Promoting broad payment and practice reform in primary care, including patient-centered medical home models for high-need applicable individuals, medical homes that address women’s unique health care needs, and models that transition primary care practices away from fee-for-service based reimbursement and toward comprehensive payment or salary-based payment. |
§ 1315a(b)(2)Selection of models to be tested(B)–(C)
(b)(2)(B)(ii)–(xxv) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (B)(xxvi) | (xxvi) | (xxvi) | ||
| Supporting ways to familiarize individuals with the availability of coverage under part B of subchapter XVIII for qualified psychologist services (as defined in section 1395x(ii) of this title). | Supporting ways to familiarize individuals with the availability of coverage under part B of subchapter XVIII for qualified psychologist services (as defined in section 1395x(ii) of this title). | |||
| (B)(xxvii) | (xxvii) | (xxvii) | ||
| Exploring ways to avoid unnecessary hospitalizations or emergency department visits for mental and behavioral health services (such as for treating depression) through use of a 24-hour, 7-day a week help line that may inform individuals about the availability of treatment options, including the availability of qualified psychologist services (as defined in section 1395x(ii) of this title). | Exploring ways to avoid unnecessary hospitalizations or emergency department visits for mental and behavioral health services (such as for treating depression) through use of a 24-hour, 7-day a week help line that may inform individuals about the availability of treatment options, including the availability of qualified psychologist services (as defined in section 1395x(ii) of this title). | |||
| (B)(xxviii) | (xxviii) [inserted: ] | |||
| [inserted: The When Minutes Count for EMS Patients Model described in subsection (h).] | ||||
| (C) | (C) Additional factors for consideration | (C) Additional factors for consideration | ||
| In selecting models for testing under subparagraph (A), the CMI may consider the following additional factors: | In selecting models for testing under subparagraph (A), the CMI may consider the following additional factors: | |||
| (C)(i) | (i) | (i) | ||
| Whether the model includes a regular process for monitoring and updating patient care plans in a manner that is consistent with the needs and preferences of applicable individuals. | Whether the model includes a regular process for monitoring and updating patient care plans in a manner that is consistent with the needs and preferences of applicable individuals. | |||
§ 1315a(f)–(h)
(b)(2)(C)(ii)–(f)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (f)(2) | (2) Use of certain funds | (2) Use of certain funds | ||
| Out of amounts appropriated under subparagraphs (B) and (C) of paragraph (1), not less than $25,000,000 shall be made available each such fiscal year to design, implement, and evaluate models under subsection (b). | Out of amounts appropriated under subparagraphs (B) and (C) of paragraph (1), not less than $25,000,000 shall be made available each such fiscal year to design, implement, and evaluate models under subsection (b). | |||
| (g) | (g) Report to Congress | (g) Report to Congress | ||
| Beginning in 2012, and not less than once every other year thereafter, the Secretary shall submit to Congress a report on activities under this section. Each such report shall describe the models tested under subsection (b), including the number of individuals described in subsection (a)(4)(A)(i) and of individuals described in subsection (a)(4)(A)(ii) participating in such models and payments made under applicable subchapters for services on behalf of such individuals, any models chosen for expansion under subsection (c), and the results from evaluations under subsection (b)(4). In addition, each such report shall provide such recommendations as the Secretary determines are appropriate for legislative action to facilitate the development and expansion of successful payment models. | Beginning in 2012, and not less than once every other year thereafter, the Secretary shall submit to Congress a report on activities under this section. Each such report shall describe the models tested under subsection (b), including the number of individuals described in subsection (a)(4)(A)(i) and of individuals described in subsection (a)(4)(A)(ii) participating in such models and payments made under applicable subchapters for services on behalf of such individuals, any models chosen for expansion under subsection (c), and the results from evaluations under subsection (b)(4). In addition, each such report shall provide such recommendations as the Secretary determines are appropriate for legislative action to facilitate the development and expansion of successful payment models. | |||
| (h) | (h) [inserted: When Minutes Count for EMS Patients Model.—] | |||
| (h)(1) | (1) [inserted: In general.—] | |||
| [inserted: For purposes of subsection (b)(2)(B)(xxviii), the When Minutes Count for EMS Patients Model described in this subsection is a model that provides supplemental payment for ground and air ambulance services under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.) for specified life-sustaining EMS medications and blood products that require immediate administration by EMS professionals to individuals with emergency medical conditions (as defined in section 1867(e)).] | ||||
| (h)(2) | (2) [inserted: Application and selection of eligible entities.—] | |||
| (h)(2)(A) | (A) [inserted: Application.—] | |||
| (h)(2)(A)(i) | (i) [inserted: In general.—] | |||
| [inserted: To be eligible to participate in the model described in paragraph (1), an eligible entity shall submit to the Secretary an application in such form, at such time, and containing such information as the Secretary may determine appropriate, which shall include at least the information described in clause (ii).] | ||||
| (h)(2)(A)(ii) | (ii) [inserted: Information described.—] | |||
| [inserted: For purposes of clause (i), the information described in this clause is such information as the Secretary determines necessary to demonstrate that the eligible entity will be able to provide sufficient data for the Secretary to be able to perform the analysis required for the report required under paragraph (5), including—] | ||||
| (h)(2)(A)(ii)(I) | (I) [inserted: ] | |||
| [inserted: data that encompasses quality of care and the outcomes of individuals receiving emergency medical services (as defined in 303(k)(13)(C) of the Controlled Substances Act); and] | ||||
| (h)(2)(A)(ii)(II) | (II) [inserted: ] | |||
| [inserted: discrete data elements associated with emergency department and inpatient services, including ICD–10 and National Emergency Medical Services Information System (NEMSIS) dispositions (NEMSIS 3.5 elements: eOutcome 0.1, eOutcome 0.2, eOutcome 10, and eOutcome 13).] | ||||
| (h)(2)(B) | (B) [inserted: Selection.—] | |||
| [inserted: The Secretary, in approving applications under this subparagraph—] | ||||
| (h)(2)(B)(i) | (i) [inserted: ] | |||
| [inserted: shall select not less than 1 eligible entity in each HHS region (as determined by the Secretary); and] | ||||
| (h)(2)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: to the extent feasible, shall select at least 1 of each type of emergency medical services agency (as such term is defined for purposes of section 303(k)(13)(D) of the Controlled Substances Act).] | ||||
| (h)(3) | (3) [inserted: Supplemental payment adjustments.—] | |||
| [inserted: The Secretary shall set payment rates for services furnished under the model described in paragraph (1) and shall make such payments in addition to any payments that eligible entities participating in the model receive for such services under section 1834 of this title. Such payment rates shall—] | ||||
| (h)(3)(A) | (A) [inserted: ] | |||
| [inserted: be calculated based on the total costs of—] | ||||
| (h)(3)(A)(i) | (i) [inserted: ] | |||
| [inserted: maintaining a sufficient supply of specified EMS medications to minimize EMS medical directors having to routinely change protocols for administration of such medications due to their persistent shortages (which shall constitute at least double the amount of average actual acquisition for such medications in the first year of the model, as determined necessary by the Secretary to ensure such sufficient supply);] | ||||
| (h)(3)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: blood products (calculated separately for each type of product used in the provision of emergency medical services, taking into account the cost of the acquisition, storage, maintenance, transport by ground and air, and administration of blood products; and administrative costs associated with blood and blood product usage and storage, including wastage;] | ||||
| (h)(3)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: maintaining a sufficient supply to serve all patients requiring the administration of specified EMS medications and blood products in the eligible entity’s primary service area (which shall not be based on the actual administration of such medications and blood products to Medicare beneficiaries); and] | ||||
| (h)(3)(A)(iv) | (iv) [inserted: ] | |||
| [inserted: maintaining software and data integration necessary for the reporting requirements described in paragraph (2)(A); and] | ||||
| (h)(3)(B) | (B) [inserted: ] | |||
| [inserted: be paid to participants as a lump sum on a monthly or quarterly basis.] | ||||
| (h)(4) | (4) [inserted: Scope of model.—] | |||
| [inserted: The Secretary shall implement the model in a manner that will provide for a sufficient number of participants in all HHS regions (as determined by the Secretary) and in varying types of geographic areas (including rural, frontier, suburban and urban) to assess and evaluate the reporting components required in the report under paragraph (5).] | ||||
| (h)(5) | (5) [inserted: Report.—] | |||
| [inserted: Not later than 1 year after the termination of the model under this subsection, the Secretary shall submit to Congress a report that includes an analysis of the following:] | ||||
| (h)(5)(A) | (A) [inserted: ] | |||
| [inserted: Whether supplemental payments for ground and air ambulance services under the model under this subsection increased the utilization of blood and blood products and lessened the adverse effects of the specified medications in shortage.] | ||||
| (h)(5)(B) | (B) [inserted: ] | |||
| [inserted: The impact of providing such specified medications and blood products on the quality of care provided, and patient outcomes including Medicare and Medicaid patient morbidity and mortality.] | ||||
| (h)(5)(C) | (C) [inserted: ] | |||
| [inserted: Whether such increased utilization of specified medications and blood products improved the quality of care and saved lives for traditionally underserved demographics and rural communities.] | ||||
| (h)(6) | (6) [inserted: Duration.—] | |||
| [inserted: The model described in paragraph (1) shall be carried out for a period of not less than 5 years.] | ||||
| (h)(7) | (7) [inserted: Definitions.—] | |||
| [inserted: In this subsection:] | ||||
| (h)(7)(A) | (A) [inserted: Specified life-saving EMS medication.—] | |||
| [inserted: The term “specified life-saving EMS medication” means the following drugs that have the meaning given the term “life-saving” in section 356(a)(1) of the Food, Drug and Cosmetic Act:] | ||||
| (h)(7)(A)(i) | (i) [inserted: ] | |||
| [inserted: Epinephrine.] | ||||
| (h)(7)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: Lidocaine.] | ||||
| (h)(7)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: Calcium.] | ||||
| (h)(7)(A)(iv) | (iv) [inserted: ] | |||
| [inserted: 0.9 percent saline solution.] | ||||
| (h)(7)(A)(v) | (v) [inserted: ] | |||
| [inserted: Lactated Ringers solution.] | ||||
| (h)(7)(A)(vi) | (vi) [inserted: ] | |||
| [inserted: Albuterol.] | ||||
| (h)(7)(A)(vii) | (vii) [inserted: ] | |||
| [inserted: Midazolam.] | ||||
| (h)(7)(A)(viii) | (viii) [inserted: ] | |||
| [inserted: 10 percent dextrose solution.] | ||||
| (h)(7)(A)(ix) | (ix) [inserted: ] | |||
| [inserted: Fentanyl.] | ||||
| (h)(7)(B) | (B) [inserted: Blood product.—] | |||
| [inserted: The term “blood product” means any therapeutic substance derived from human blood, including whole blood and other blood components for transfusion, and plasma-derived medicinal products.] | ||||
| (h)(7)(C) | (C) [inserted: Eligible entity.—] | |||
| [inserted: The term “eligible entity” means an emergency medical services agency (as defined in section 303(k)(13)(D) of the Controlled Substances Act).] | ||||